京尼平苷在制备治疗乳腺增生药物中的应用
Genipin reduces breast hyperplasia symptoms by regulating sex hormone levels, solving the problems of large side effects of Western and traditional Chinese medicine hormone drugs and poor adaptability of traditional Chinese medicine combinations in existing technologies, and providing an effective single-drug treatment option.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- JIANGSU CANCER HOSPITAL
- Filing Date
- 2023-10-24
- Publication Date
- 2026-07-17
AI Technical Summary
In existing technologies, Western medicine hormone drugs for treating breast hyperplasia have side effects, traditional Chinese medicine combinations have poor therapeutic effects and poor patient adaptability, and there is a lack of effective single drugs for long-term treatment of breast hyperplasia.
Genipin is used as a single active ingredient or in combination with other active ingredients to prepare an oral formulation for the treatment of breast hyperplasia. It reduces nipple height and breast diameter in patients with breast hyperplasia by lowering prolactin (PRL) and estradiol (E2) levels and increasing progesterone (PROG) levels.
Genipin significantly reduces nipple height and breast diameter in patients with mammary hyperplasia, regulates sex hormone levels, has a clear therapeutic effect, and is suitable for long-term use.
Smart Images
Figure SMS_3 
Figure SMS_6